Summary & Overview
HCPCS G2208: Omission of Adjuvant Chemotherapy plus HER2-Targeted Therapy
HCPCS Level II code G2208 documents that a patient did not receive an adjuvant treatment course that included both chemotherapy and HER2-targeted therapy. Nationally, this code matters for tracking gaps in guideline-recommended systemic adjuvant treatment for HER2-positive cancers, quality measurement, and claims-based identification of treatment omission. It is used by payers and quality programs to flag cases where combined adjuvant therapy was not completed or initiated as expected.
Key payers commonly involved in analyses of G2208 include Aetna, Blue Cross Blue Shield plans, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical meaning, typical sites of service, and implications for claims processing. The publication outlines how G2208 is applied in billing, typical use cases in oncology outpatient and hospital-based settings, and what benchmark and policy topics are relevant when tracking omission of combined chemotherapy and HER2-targeted therapy. Where available, readers will also see discussion of coding context, common modifiers, and how this code interacts with programmatic quality measurement. Data not available in the input will be noted as such.
Billing Code Overview
HCPCS Level II code G2208 indicates that a patient did not receive an adjuvant treatment course that included both chemotherapy and HER2-targeted therapy. This code applies to documentation of omission of the combined post-operative systemic therapies in patients for whom such combined treatment would normally be considered.
-
Service type: Omission of combined adjuvant systemic therapy (chemotherapy plus HER2-targeted therapy)
-
Typical site of service: Oncology outpatient clinics or hospital-based oncology units where adjuvant systemic therapy would be delivered
Clinical & Coding Specifications
Clinical Context
A 56-year-old woman with newly diagnosed stage II HER2-positive invasive ductal carcinoma undergoes definitive breast surgery (lumpectomy with sentinel lymph node biopsy). Pathology confirms node-negative disease but high-risk features. The oncology team recommends an adjuvant regimen combining multi-agent chemotherapy plus HER2-targeted therapy. The patient declines chemotherapy due to prior severe chemotherapy-related toxicity from a prior cancer and elects surveillance; alternatively, comorbid cardiomyopathy precludes safe HER2-targeted therapy. Billing for the clinical encounter documents that the patient did not receive the recommended adjuvant treatment course including both chemotherapy and HER2-targeted therapy, reported with G2208.
Clinical workflow: the surgical team documents tumor pathology and multidisciplinary tumor board recommendation for adjuvant chemo plus HER2-directed therapy; the medical oncology visit records contraindication or refusal, informed consent discussion, alternative plans, and care coordination notes. Billing staff append G2208 on the encounter claim to indicate omission of the combined adjuvant course. Typical sites of service include the outpatient oncology clinic, hospital outpatient department, or ambulatory surgery center for the operative encounter and subsequent medical oncology visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |